TY - JOUR
T1 - A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue
AU - Petr, Jan
AU - Hogeboom, Louise
AU - Nikulin, Pavel
AU - Wiegers, Evita
AU - Schroyen, Gwen
AU - Kallehauge, Jesper
AU - Chmelík, Marek
AU - Clement, Patricia
AU - Nechifor, Ruben E.
AU - Fodor, Liviu Andrei
AU - De Witt Hamer, Philip C.
AU - Barkhof, Frederik
AU - Pernet, Cyril
AU - Lequin, Maarten
AU - Deprez, Sabine
AU - Jančálek, Radim
AU - Mutsaerts, Henk J.M.M.
AU - Pizzini, Francesca B.
AU - Emblem, Kyrre E.
AU - Keil, Vera C.
N1 - Funding Information:
Open Access funding enabled and organized by Projekt DEAL. This project is funded by European Cooperation in Science and Technology, CA18206, Jan Petr.
Publisher Copyright:
© 2021, The Author(s).
© 2021. The Author(s).
PY - 2022/2
Y1 - 2022/2
N2 - Cancer therapy for both central nervous system (CNS) and non-CNS tumors has been previously associated with transient and long-term cognitive deterioration, commonly referred to as ‘chemo fog’. This therapy-related damage to otherwise normal-appearing brain tissue is reported using post-mortem neuropathological analysis. Although the literature on monitoring therapy effects on structural magnetic resonance imaging (MRI) is well established, such macroscopic structural changes appear relatively late and irreversible. Early quantitative MRI biomarkers of therapy-induced damage would potentially permit taking these treatment side effects into account, paving the way towards a more personalized treatment planning. This systematic review (PROSPERO number 224196) provides an overview of quantitative tomographic imaging methods, potentially identifying the adverse side effects of cancer therapy in normal-appearing brain tissue. Seventy studies were obtained from the MEDLINE and Web of Science databases. Studies reporting changes in normal-appearing brain tissue using MRI, PET, or SPECT quantitative biomarkers, related to radio-, chemo-, immuno-, or hormone therapy for any kind of solid, cystic, or liquid tumor were included. The main findings of the reviewed studies were summarized, providing also the risk of bias of each study assessed using a modified QUADAS-2 tool. For each imaging method, this review provides the methodological background, and the benefits and shortcomings of each method from the imaging perspective. Finally, a set of recommendations is proposed to support future research.
AB - Cancer therapy for both central nervous system (CNS) and non-CNS tumors has been previously associated with transient and long-term cognitive deterioration, commonly referred to as ‘chemo fog’. This therapy-related damage to otherwise normal-appearing brain tissue is reported using post-mortem neuropathological analysis. Although the literature on monitoring therapy effects on structural magnetic resonance imaging (MRI) is well established, such macroscopic structural changes appear relatively late and irreversible. Early quantitative MRI biomarkers of therapy-induced damage would potentially permit taking these treatment side effects into account, paving the way towards a more personalized treatment planning. This systematic review (PROSPERO number 224196) provides an overview of quantitative tomographic imaging methods, potentially identifying the adverse side effects of cancer therapy in normal-appearing brain tissue. Seventy studies were obtained from the MEDLINE and Web of Science databases. Studies reporting changes in normal-appearing brain tissue using MRI, PET, or SPECT quantitative biomarkers, related to radio-, chemo-, immuno-, or hormone therapy for any kind of solid, cystic, or liquid tumor were included. The main findings of the reviewed studies were summarized, providing also the risk of bias of each study assessed using a modified QUADAS-2 tool. For each imaging method, this review provides the methodological background, and the benefits and shortcomings of each method from the imaging perspective. Finally, a set of recommendations is proposed to support future research.
KW - Chemotherapy
KW - Cognitive decline
KW - Long-term adverse effects
KW - Neuroimaging
KW - Radiotherapy
KW - Brain/diagnostic imaging
KW - Magnetic Resonance Imaging
KW - Cognition Disorders
KW - Humans
KW - Neoplasms/diagnostic imaging
UR - http://www.scopus.com/inward/record.url?scp=85121349095&partnerID=8YFLogxK
U2 - 10.1007/s10334-021-00985-2
DO - 10.1007/s10334-021-00985-2
M3 - Review article
C2 - 34919195
AN - SCOPUS:85121349095
SN - 0968-5243
VL - 35
SP - 163
EP - 186
JO - Magnetic Resonance Materials in Physics, Biology and Medicine
JF - Magnetic Resonance Materials in Physics, Biology and Medicine
IS - 1
ER -